Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

BACKGROUND: In locally advanced Non-Small-Cell Lung Cancer (LA-NSCLC) patients treated with chemoradiotherapy (CRT), optimal surrogate endpoint for cure has not been fully investigated. METHODS: The clinical records of LA-NSCLC patients treated with concurrent CRT at Shizuoka Cancer Center between S...

詳細記述

保存先:
書誌詳細
主要な著者: Akamatsu, Hiroaki, Mori, Keita, Naito, Tateaki, Imai, Hisao, Ono, Akira, Shukuya, Takehito, Taira, Tetsuhiko, Kenmotsu, Hirotsugu, Murakami, Haruyasu, Endo, Masahiro, Harada, Hideyuki, Takahashi, Toshiaki, Yamamoto, Nobuyuki
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2014
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3901557/
https://ncbi.nlm.nih.gov/pubmed/24422706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-18
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料